In March 2025, Roche entered into an outstanding licensing agreement and collaboration with Zealand Pharma for co-commercializing and co-developing petrelintide as a standalone therapy and a fixed-dose combination with Roches lead incretin asset CT-388
Youve likely heard about the incredible results of GLP-1 (glucagon-like peptide-1) medications, such as semaglutide, liraglutide, and tirzepatide, for weight loss in obese and overweight patients and type 2 diabetes mellitus
Additionally, Copper Peptides have antioxidant properties that protect the skin from free radicals and promote overall skin health
(1) Classical GPx (GPx1) is reported to be expressed in red blood cells and liver, lung, and kidney tissues and is located in the cytosol, nucleus, and mitochondria
What is the difference between FDA-approved brand-name drugs and compounded GLP-1 medications